Adverse events during perampanel adjunctive therapy in intractable epilepsy

Song Ee Youn, Se Hee Kim, Ara Ko, Sun Ho Lee, Young Mock Lee, Hoon Chul Kang, Joon Soo Lee, Heung Dong Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background and Purpose Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be elucidated. Methods Eighty-five patients received perampanel between March 2016 and August 2016. Patients were divided into two groups according to their dosing schedule: rapid dose titration (2-mg increments at intervals of 1 to 2 weeks) and slow dose titration (2-mg increments at intervals of at least 3 weeks). Seizure frequency and adverse events were analyzed over 3 months. Results Adverse events were reported by 47 (58%) of the 81 patients analyzed, with 12 (15%) patients discontinuing perampanel due to adverse events. Common adverse events included dizziness (n=30, 37%), aggressive mood and behavior (n=19, 24%), gait disturbance (n=16, 20%), and sleep problems (n=10, 12.4%). The overall adverse events were similar in the slow-titration group (38 of 61 patients) and the rapid-titration group (8 of 20 patients, p=0.081). However, none of the 20 patients in the slow-titration group experienced gait disturbance, compared with 16 of the 61 patients in the rapid-titration group (p=0.009), while appetite change was experienced by 4 patients in the slow-titration group but only 1 in the rapid-titration group (p=0.003). No relationship was noted between adverse events and the maximum dose of perampanel (p=0.116). Sex differences were observed, with the response to perampanel being better and the rate of adverse events being higher in females (p=0.015 and p=0.046, respectively). Conclusions Slow titration of perampanel may reduce perampanel-related adverse events.

Original languageEnglish
Pages (from-to)296-302
Number of pages7
JournalJournal of Clinical Neurology (Korea)
Volume14
Issue number3
DOIs
Publication statusPublished - 2018 Jul

Fingerprint

Therapeutics
Gait
Isoxazoles
perampanel
Drug Resistant Epilepsy
AMPA Receptors
Dizziness
Appetite
Sex Characteristics
Epilepsy
Appointments and Schedules
Sleep
Seizures
propionic acid

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Youn, Song Ee ; Kim, Se Hee ; Ko, Ara ; Lee, Sun Ho ; Lee, Young Mock ; Kang, Hoon Chul ; Lee, Joon Soo ; Kim, Heung Dong. / Adverse events during perampanel adjunctive therapy in intractable epilepsy. In: Journal of Clinical Neurology (Korea). 2018 ; Vol. 14, No. 3. pp. 296-302.
@article{37b9df0d25884610a9b822cc0ea5e02d,
title = "Adverse events during perampanel adjunctive therapy in intractable epilepsy",
abstract = "Background and Purpose Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be elucidated. Methods Eighty-five patients received perampanel between March 2016 and August 2016. Patients were divided into two groups according to their dosing schedule: rapid dose titration (2-mg increments at intervals of 1 to 2 weeks) and slow dose titration (2-mg increments at intervals of at least 3 weeks). Seizure frequency and adverse events were analyzed over 3 months. Results Adverse events were reported by 47 (58{\%}) of the 81 patients analyzed, with 12 (15{\%}) patients discontinuing perampanel due to adverse events. Common adverse events included dizziness (n=30, 37{\%}), aggressive mood and behavior (n=19, 24{\%}), gait disturbance (n=16, 20{\%}), and sleep problems (n=10, 12.4{\%}). The overall adverse events were similar in the slow-titration group (38 of 61 patients) and the rapid-titration group (8 of 20 patients, p=0.081). However, none of the 20 patients in the slow-titration group experienced gait disturbance, compared with 16 of the 61 patients in the rapid-titration group (p=0.009), while appetite change was experienced by 4 patients in the slow-titration group but only 1 in the rapid-titration group (p=0.003). No relationship was noted between adverse events and the maximum dose of perampanel (p=0.116). Sex differences were observed, with the response to perampanel being better and the rate of adverse events being higher in females (p=0.015 and p=0.046, respectively). Conclusions Slow titration of perampanel may reduce perampanel-related adverse events.",
author = "Youn, {Song Ee} and Kim, {Se Hee} and Ara Ko and Lee, {Sun Ho} and Lee, {Young Mock} and Kang, {Hoon Chul} and Lee, {Joon Soo} and Kim, {Heung Dong}",
year = "2018",
month = "7",
doi = "10.3988/jcn.2018.14.3.296",
language = "English",
volume = "14",
pages = "296--302",
journal = "Journal of Clinical Neurology (Korea)",
issn = "1738-6586",
publisher = "Korean Neurological Association",
number = "3",

}

Adverse events during perampanel adjunctive therapy in intractable epilepsy. / Youn, Song Ee; Kim, Se Hee; Ko, Ara; Lee, Sun Ho; Lee, Young Mock; Kang, Hoon Chul; Lee, Joon Soo; Kim, Heung Dong.

In: Journal of Clinical Neurology (Korea), Vol. 14, No. 3, 07.2018, p. 296-302.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adverse events during perampanel adjunctive therapy in intractable epilepsy

AU - Youn, Song Ee

AU - Kim, Se Hee

AU - Ko, Ara

AU - Lee, Sun Ho

AU - Lee, Young Mock

AU - Kang, Hoon Chul

AU - Lee, Joon Soo

AU - Kim, Heung Dong

PY - 2018/7

Y1 - 2018/7

N2 - Background and Purpose Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be elucidated. Methods Eighty-five patients received perampanel between March 2016 and August 2016. Patients were divided into two groups according to their dosing schedule: rapid dose titration (2-mg increments at intervals of 1 to 2 weeks) and slow dose titration (2-mg increments at intervals of at least 3 weeks). Seizure frequency and adverse events were analyzed over 3 months. Results Adverse events were reported by 47 (58%) of the 81 patients analyzed, with 12 (15%) patients discontinuing perampanel due to adverse events. Common adverse events included dizziness (n=30, 37%), aggressive mood and behavior (n=19, 24%), gait disturbance (n=16, 20%), and sleep problems (n=10, 12.4%). The overall adverse events were similar in the slow-titration group (38 of 61 patients) and the rapid-titration group (8 of 20 patients, p=0.081). However, none of the 20 patients in the slow-titration group experienced gait disturbance, compared with 16 of the 61 patients in the rapid-titration group (p=0.009), while appetite change was experienced by 4 patients in the slow-titration group but only 1 in the rapid-titration group (p=0.003). No relationship was noted between adverse events and the maximum dose of perampanel (p=0.116). Sex differences were observed, with the response to perampanel being better and the rate of adverse events being higher in females (p=0.015 and p=0.046, respectively). Conclusions Slow titration of perampanel may reduce perampanel-related adverse events.

AB - Background and Purpose Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be elucidated. Methods Eighty-five patients received perampanel between March 2016 and August 2016. Patients were divided into two groups according to their dosing schedule: rapid dose titration (2-mg increments at intervals of 1 to 2 weeks) and slow dose titration (2-mg increments at intervals of at least 3 weeks). Seizure frequency and adverse events were analyzed over 3 months. Results Adverse events were reported by 47 (58%) of the 81 patients analyzed, with 12 (15%) patients discontinuing perampanel due to adverse events. Common adverse events included dizziness (n=30, 37%), aggressive mood and behavior (n=19, 24%), gait disturbance (n=16, 20%), and sleep problems (n=10, 12.4%). The overall adverse events were similar in the slow-titration group (38 of 61 patients) and the rapid-titration group (8 of 20 patients, p=0.081). However, none of the 20 patients in the slow-titration group experienced gait disturbance, compared with 16 of the 61 patients in the rapid-titration group (p=0.009), while appetite change was experienced by 4 patients in the slow-titration group but only 1 in the rapid-titration group (p=0.003). No relationship was noted between adverse events and the maximum dose of perampanel (p=0.116). Sex differences were observed, with the response to perampanel being better and the rate of adverse events being higher in females (p=0.015 and p=0.046, respectively). Conclusions Slow titration of perampanel may reduce perampanel-related adverse events.

UR - http://www.scopus.com/inward/record.url?scp=85051628357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051628357&partnerID=8YFLogxK

U2 - 10.3988/jcn.2018.14.3.296

DO - 10.3988/jcn.2018.14.3.296

M3 - Article

AN - SCOPUS:85051628357

VL - 14

SP - 296

EP - 302

JO - Journal of Clinical Neurology (Korea)

JF - Journal of Clinical Neurology (Korea)

SN - 1738-6586

IS - 3

ER -